Adtalem Global Education First Quarter Fiscal Year 2025 Results; Guidance Raised
Total enrollment up 11.2% YoY
Revenue up 13.2% YoY
Diluted earnings per share
First quarter highlights
- Total student enrollment 90,140, up 11.2% year-over-year
-
Revenue
$417.4 million , up 13.2% year-over-year -
Chamberlain University seventh straight quarter of total enrollment growth, up 11.7% year-over-year, highest total enrollment in university history -
Walden University fifth straight quarter of total enrollment growth, up 12.2% year-over-year - Medical and Veterinary segment fourth straight enrollment period of sequentially improved year-over-year total enrollment trends
-
Strong momentum starting second year of three-year Growth with Purpose strategy, GAAP net income
$46.2 million and adjusted EBITDA$96.7 million , up 20.1% year-over-year
Capital allocation
-
Repurchased
$34 million of shares,$178 million remaining under$300 million Board authorized share repurchase program throughJanuary 2027 -
Repriced
$253 million Term Loan B onAug. 21, 2024 , reducing interest rate by 75 bps -
Net leverage 1.0x as of
Sept. 30, 2024
Fiscal year 2025 guidance
-
Revenue
$1,690 million to$1,730 million -
Adjusted earnings per share
$5.75 to$5.95
“We entered year two of our three-year Growth with Purpose strategy with strong momentum, further integrating our tech-enabled platform and expanding our impact through innovative partnerships,” said
Financial Highlights
Selected financial data for the three months ended
-
Revenue of
$417.4 million increased 13.2% compared with the prior year. -
Operating income of
$70.2 million , compared with$28.2 million in the prior year; adjusted operating income of$75.8 million , compared with$63.3 million in the prior year. -
Net income of
$46.2 million , compared with$10.6 million in the prior year; adjusted net income of$50.5 million , compared with$39.4 million in the prior year. -
Diluted earnings per share of
$1.18 , compared with$0.25 in the prior year; adjusted earnings per share of$1.29 , compared with$0.93 in the prior year. -
Adjusted EBITDA of
$96.7 million , compared with$80.5 million in the prior year; adjusted EBITDA margin of 23.2%, compared with 21.8% in the prior year.
Business Highlights
-
Chamberlain University expanded its specialized nursing education Practice Ready. Specialty Focused.™ (PRSF) model through a partnership with theOncology Nursing Society (ONS), offering an introduction to caring for cancer patients and their families. The ONS offering joins other specializations in the PRSF model, including critical care, emergency nursing, nephrology, home healthcare and perioperative nursing. -
Adtalem announced a partnership with Hippocratic AI to develop a new curriculum focused on training healthcare professionals in the use of AI technologies. The initiative includes the first-ever AI certification, designed for both
Chamberlain University andWalden University students, as well as practicing clinicians, focused on essential skills to effectively evaluate, navigate and ethically utilize AI tools in patient care. -
Ross University School of Veterinary Medicine ranked third for most graduates placed into the highly sought after Veterinary Internship and Residency Matching Program™ (VIRMP) for 2024. Our students matched into specialties including anesthesia, large animal surgery, medical oncology, veterinary dermatology and radiology. -
Chamberlain University's Bachelor of Science in Nursing and Master of Science in Nursing degree programs received continuing accreditation by theCommission on Collegiate Nursing Education (CCNE) for the maximum accreditation period of 10 years. Chamberlain's Doctor of Nursing Practice degree program also recently received continuing accreditation by theNational League for Nursing Commission for Nursing Education Accreditation (NLN CNEA) for the accreditation period of 10 years. -
Adtalem recently released its 2024 Sustainability Report, which highlights the Company’s collective efforts to address critical workforce shortages in the
U.S. healthcare system by strengthening pathways to high-quality education and promoting health equity.
Segment Highlights
Chamberlain
$ in millions |
|
Three Months Ended
|
||
|
|
2024 |
2023 |
% Change |
Revenue |
|
|
|
17.8% |
Operating Income |
|
|
|
6.8% |
Adj. Operating Income |
|
|
|
14.4% |
Adj. EBITDA |
|
|
|
17.2% |
Total Students (1) |
|
38,987 |
34,889 |
11.7% |
- Total student enrollment increased 11.7% compared with the prior year, driven by continued growth in pre-licensure and post-licensure nursing programs.
Walden
$ in millions |
|
Three Months Ended
|
||
|
|
2024 |
2023 |
% Change |
Revenue |
|
|
|
14.1% |
Operating Income |
|
|
|
1,955.6% |
Adj. Operating Income |
|
|
|
37.0% |
Adj. EBITDA |
|
|
|
35.9% |
Total Students (1) |
|
45,979 |
40,975 |
12.2% |
- Total student enrollment increased 12.2% compared with the prior year, driven by growth in healthcare and non-healthcare programs.
Medical and Veterinary
$ in millions |
|
Three Months Ended
|
||
|
|
2024 |
2023 |
% Change |
Revenue |
|
|
|
3.9% |
Operating Income |
|
|
|
2.1% |
Adj. Operating Income |
|
|
|
1.7% |
Adj. EBITDA |
|
|
|
0.7% |
Total Students (1) |
|
5,174 |
5,209 |
(0.7)% |
- Total student enrollment decreased 0.7% compared with the prior year, driven by declines at medical.
Fiscal Year 2025 Outlook
Adtalem raises guidance for fiscal year 2025, with revenue in the range of
Conference Call and Webcast Information
Adtalem will hold a conference call to discuss its first quarter fiscal year 2025 results today at
The call can be accessed by dialing +1 877-407-6184 (
Adtalem will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (
About
Cautionary Disclosure Regarding Forward-Looking Statements
Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Adtalem’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risks and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our most recent Annual Report on Form 10-K filed with the
A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Adtalem's results in accordance with GAAP.
1 Represents total students attending sessions during each institution’s most recent enrollment period in Q1 FY 2025 and Q1 FY 2024.
Consolidated Balance Sheets (unaudited) (in thousands) |
||||||
|
|
|
|
|
||
|
|
|
|
|
||
|
2024 |
|
2024 |
|
||
Assets: |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
$ |
264,798 |
|
$ |
219,306 |
|
Restricted cash |
|
2,074 |
|
|
1,896 |
|
Accounts and financing receivables, net |
|
171,509 |
|
|
126,833 |
|
Prepaid expenses and other current assets |
|
78,533 |
|
|
70,050 |
|
Total current assets |
|
516,914 |
|
|
418,085 |
|
Noncurrent assets: |
|
|
|
|
||
Property and equipment, net |
|
244,503 |
|
|
248,524 |
|
Operating lease assets |
|
171,921 |
|
|
176,755 |
|
Deferred income taxes |
|
33,454 |
|
|
49,088 |
|
Intangible assets, net |
|
773,889 |
|
|
776,694 |
|
|
|
961,262 |
|
|
961,262 |
|
Other assets, net |
|
107,939 |
|
|
103,184 |
|
Assets held for sale |
|
7,825 |
|
|
7,825 |
|
Total noncurrent assets |
|
2,300,793 |
|
|
2,323,332 |
|
Total assets |
$ |
2,817,707 |
|
$ |
2,741,417 |
|
|
|
|
|
|
||
Liabilities and shareholders' equity: |
|
|
|
|
||
Current liabilities: |
|
|
|
|
||
Accounts payable |
$ |
91,421 |
|
$ |
102,626 |
|
Accrued payroll and benefits |
|
49,839 |
|
|
71,373 |
|
Accrued liabilities |
|
87,212 |
|
|
96,957 |
|
Deferred revenue |
|
290,571 |
|
|
185,272 |
|
Current operating lease liabilities |
|
32,266 |
|
|
31,429 |
|
Total current liabilities |
|
551,309 |
|
|
487,657 |
|
Noncurrent liabilities: |
|
|
|
|
||
Long-term debt |
|
649,318 |
|
|
648,712 |
|
Long-term operating lease liabilities |
|
161,757 |
|
|
167,712 |
|
Deferred income taxes |
|
30,348 |
|
|
29,526 |
|
Other liabilities |
|
35,023 |
|
|
38,675 |
|
Total noncurrent liabilities |
|
876,446 |
|
|
884,625 |
|
Total liabilities |
|
1,427,755 |
|
|
1,372,282 |
|
Commitments and contingencies |
|
|
|
|
||
Total shareholders' equity |
|
1,389,952 |
|
|
1,369,135 |
|
Total liabilities and shareholders' equity |
$ |
2,817,707 |
|
$ |
2,741,417 |
|
|
Consolidated Statements of Income (unaudited) (in thousands, except per share data) |
||||||||
|
|
|
|
|
||||
|
Three Months Ended |
|
||||||
|
|
|
||||||
|
|
2024 |
|
|
|
2023 |
|
|
Revenue |
$ |
417,400 |
|
|
$ |
368,845 |
|
|
Operating cost and expense: |
|
|
|
|
||||
Cost of educational services |
|
185,995 |
|
|
|
168,618 |
|
|
Student services and administrative expense |
|
159,073 |
|
|
|
166,095 |
|
|
Restructuring expense |
|
2,094 |
|
|
|
676 |
|
|
Business integration expense |
|
— |
|
|
|
5,262 |
|
|
Total operating cost and expense |
|
347,162 |
|
|
|
340,651 |
|
|
Operating income |
|
70,238 |
|
|
|
28,194 |
|
|
Interest expense |
|
(14,482 |
) |
|
|
(15,657 |
) |
|
Other income, net |
|
2,646 |
|
|
|
2,214 |
|
|
Income from continuing operations before income taxes |
|
58,402 |
|
|
|
14,751 |
|
|
Provision for income taxes |
|
(12,157 |
) |
|
|
(2,792 |
) |
|
Income from continuing operations |
|
46,245 |
|
|
|
11,959 |
|
|
Discontinued operations: |
|
|
|
|
||||
Loss from discontinued operations before income taxes |
|
(107 |
) |
|
|
(1,765 |
) |
|
Benefit from income taxes |
|
27 |
|
|
|
452 |
|
|
Loss from discontinued operations |
|
(80 |
) |
|
|
(1,313 |
) |
|
Net income and comprehensive income |
$ |
46,165 |
|
|
$ |
10,646 |
|
|
|
|
|
|
|
||||
Earnings (loss) per share: |
|
|
|
|
||||
Basic: |
|
|
|
|
||||
Continuing operations |
$ |
1.23 |
|
|
$ |
0.29 |
|
|
Discontinued operations |
$ |
(0.00 |
) |
|
$ |
(0.03 |
) |
|
Total basic earnings per share |
$ |
1.22 |
|
|
$ |
0.26 |
|
|
Diluted: |
|
|
|
|
||||
Continuing operations |
$ |
1.18 |
|
|
$ |
0.28 |
|
|
Discontinued operations |
$ |
(0.00 |
) |
|
$ |
(0.03 |
) |
|
Total diluted earnings per share |
$ |
1.18 |
|
|
$ |
0.25 |
|
|
|
|
|
|
|
||||
Weighted-average shares outstanding: |
|
|
|
|
||||
Basic shares |
|
37,721 |
|
|
|
41,399 |
|
|
Diluted shares |
|
39,109 |
|
|
|
42,184 |
|
|
|
|
Consolidated Statements of Cash Flows (unaudited) (in thousands) |
||||||||
|
|
|
|
|
||||
|
Three Months Ended |
|
||||||
|
|
|
||||||
|
|
2024 |
|
|
|
2023 |
|
|
Operating activities: |
|
|
|
|
||||
Net income |
$ |
46,165 |
|
|
$ |
10,646 |
|
|
Loss from discontinued operations |
|
80 |
|
|
|
1,313 |
|
|
Income from continuing operations |
|
46,245 |
|
|
|
11,959 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Stock-based compensation |
|
9,451 |
|
|
|
7,455 |
|
|
Amortization and impairments to operating lease assets |
|
6,948 |
|
|
|
8,765 |
|
|
Depreciation |
|
9,803 |
|
|
|
9,338 |
|
|
Amortization of acquired intangible assets |
|
2,805 |
|
|
|
10,677 |
|
|
Amortization of debt discount and issuance costs |
|
1,113 |
|
|
|
1,155 |
|
|
Provision for bad debts |
|
13,720 |
|
|
|
10,226 |
|
|
Deferred income taxes |
|
16,456 |
|
|
|
2,165 |
|
|
Loss on disposals of property and equipment |
|
107 |
|
|
|
38 |
|
|
(Gain) loss on investments |
|
(613 |
) |
|
|
447 |
|
|
Changes in assets and liabilities: |
|
|
|
|
||||
Accounts and financing receivables |
|
(56,803 |
) |
|
|
(54,867 |
) |
|
Prepaid expenses and other current assets |
|
(7,389 |
) |
|
|
(5,532 |
) |
|
Cloud computing implementation assets |
|
(7,888 |
) |
|
|
(4,224 |
) |
|
Accounts payable |
|
(8,508 |
) |
|
|
(2,818 |
) |
|
Accrued payroll and benefits |
|
(21,501 |
) |
|
|
(8,882 |
) |
|
Accrued liabilities |
|
(8,467 |
) |
|
|
13,770 |
|
|
Deferred revenue |
|
106,156 |
|
|
|
98,658 |
|
|
Operating lease liabilities |
|
(7,232 |
) |
|
|
(10,053 |
) |
|
Other assets and liabilities |
|
(4,836 |
) |
|
|
(2,163 |
) |
|
Net cash provided by operating activities-continuing operations |
|
89,567 |
|
|
|
86,114 |
|
|
Net cash (used in) provided by operating activities-discontinued operations |
|
(251 |
) |
|
|
8,959 |
|
|
Net cash provided by operating activities |
|
89,316 |
|
|
|
95,073 |
|
|
Investing activities: |
|
|
|
|
||||
Capital expenditures |
|
(10,414 |
) |
|
|
(10,434 |
) |
|
Proceeds from sales of marketable securities |
|
2,187 |
|
|
|
400 |
|
|
Purchases of marketable securities |
|
(1,308 |
) |
|
|
(300 |
) |
|
Net cash used in investing activities |
|
(9,535 |
) |
|
|
(10,334 |
) |
|
Financing activities: |
|
|
|
|
||||
Proceeds from exercise of stock options |
|
9,498 |
|
|
|
550 |
|
|
Employee taxes paid on withholding shares |
|
(10,717 |
) |
|
|
(5,651 |
) |
|
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
298 |
|
|
|
190 |
|
|
Repurchases of common stock for treasury |
|
(33,190 |
) |
|
|
(90,477 |
) |
|
Proceeds from issuance of long-term debt |
|
9,873 |
|
|
|
— |
|
|
Repayments of long-term debt |
|
(9,873 |
) |
|
|
— |
|
|
Net cash used in financing activities |
|
(34,111 |
) |
|
|
(95,388 |
) |
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
45,670 |
|
|
|
(10,649 |
) |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
221,202 |
|
|
|
275,075 |
|
|
Cash, cash equivalents and restricted cash at end of period |
$ |
266,872 |
|
|
$ |
264,426 |
|
|
Non-cash investing and financing activities: |
|
|
|
|
||||
Accrued capital expenditures |
$ |
4,193 |
|
|
$ |
6,087 |
|
|
Accrued liability for repurchases of common stock |
$ |
800 |
|
|
$ |
3,600 |
|
|
Accrued excise tax on share repurchases |
$ |
3,259 |
|
|
$ |
1,928 |
|
|
|
|
Segment Information (unaudited) (in thousands) |
|||||||||||||
|
Three Months Ended |
||||||||||||
|
|
||||||||||||
|
|
|
|
|
Increase/(Decrease) |
|
|||||||
|
|
2024 |
|
|
|
2023 |
|
|
$ |
|
% |
|
|
Revenue: |
|
|
|
|
|
|
|
|
|||||
Chamberlain |
$ |
167,930 |
|
|
$ |
142,596 |
|
|
$ |
25,334 |
|
17.8 |
% |
Walden |
|
161,513 |
|
|
|
141,608 |
|
|
|
19,905 |
|
14.1 |
% |
Medical and Veterinary |
|
87,957 |
|
|
|
84,641 |
|
|
|
3,316 |
|
3.9 |
% |
Total consolidated revenue |
$ |
417,400 |
|
|
$ |
368,845 |
|
|
$ |
48,555 |
|
13.2 |
% |
Operating income (loss): |
|
|
|
|
|
|
|
|
|||||
Chamberlain |
$ |
25,974 |
|
|
$ |
24,324 |
|
|
$ |
1,650 |
|
6.8 |
% |
Walden |
|
39,837 |
|
|
|
1,938 |
|
|
|
37,899 |
|
1,955.6 |
% |
Medical and Veterinary |
|
14,671 |
|
|
|
14,363 |
|
|
|
308 |
|
2.1 |
% |
Home Office |
|
(10,244 |
) |
|
|
(12,431 |
) |
|
|
2,187 |
|
17.6 |
% |
Total consolidated operating income |
$ |
70,238 |
|
|
$ |
28,194 |
|
|
$ |
42,044 |
|
149.1 |
% |
Non-GAAP Financial Measures and Reconciliations
We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Adtalem’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:
Adjusted net income (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, litigation reserve, debt modification costs, and loss from discontinued operations.
Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Adtalem’s diluted earnings per share adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, litigation reserve, debt modification costs, and loss from discontinued operations.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Adtalem’s operating income adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, litigation reserve, and debt modification costs. This measure is applied on a consolidated and segment basis, depending on the context of the discussion.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for loss from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, business integration expense, litigation reserve, and debt modification costs. This measure is applied on a consolidated and segment basis, depending on the context of the discussion. Provision for income taxes, interest expense, and other income, net is not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with operating income.
Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.
Net debt – Defined as long-term debt less cash and cash equivalents.
Net leverage – Defined as net debt divided by adjusted EBITDA.
A description of special items in our non-GAAP financial measures described above are as follows:
- Restructuring expense primarily related to workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Adtalem’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense.
- Business integration expense include expenses related to the Walden acquisition and certain costs related to growth transformation initiatives. We do not include normal, recurring, cash operating expenses in our business integration expense.
- Amortization of acquired intangible assets.
- Amortization of cloud computing implementation assets.
- Reserves related to significant litigation and debt modification costs related to refinancing our Term Loan B loan.
-
Loss from discontinued operations includes expense from ongoing litigation costs and settlements related to the
DeVry University andCarrington College divestitures.
Non-GAAP Operating Income by Segment (unaudited) (in thousands) |
||||||||||||||||
|
|
Three Months Ended |
||||||||||||||
|
|
|
||||||||||||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
|||||||
|
|
2024 |
|
2023 |
|
$ |
|
% |
|
|||||||
Chamberlain: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
25,974 |
|
|
$ |
24,324 |
|
|
$ |
1,650 |
|
|
6.8 |
|
% |
Restructuring expense |
|
|
1,858 |
|
|
|
— |
|
|
|
1,858 |
|
|
|
|
|
Adjusted operating income (non-GAAP) |
|
$ |
27,832 |
|
|
$ |
24,324 |
|
|
$ |
3,508 |
|
|
14.4 |
|
% |
Operating margin (GAAP) |
|
|
15.5 |
|
% |
|
17.1 |
|
% |
|
|
|
|
|
||
Operating margin (non-GAAP) |
|
|
16.6 |
|
% |
|
17.1 |
|
% |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Walden: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
39,837 |
|
|
$ |
1,938 |
|
|
$ |
37,899 |
|
|
1,955.6 |
|
% |
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
|
10,677 |
|
|
|
(7,872 |
) |
|
|
|
|
Litigation reserve |
|
|
— |
|
|
|
18,500 |
|
|
|
(18,500 |
) |
|
|
|
|
Adjusted operating income (non-GAAP) |
|
$ |
42,642 |
|
|
$ |
31,115 |
|
|
$ |
11,527 |
|
|
37.0 |
|
% |
Operating margin (GAAP) |
|
|
24.7 |
|
% |
|
1.4 |
|
% |
|
|
|
|
|
||
Operating margin (non-GAAP) |
|
|
26.4 |
|
% |
|
22.0 |
|
% |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical and Veterinary: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
14,671 |
|
|
$ |
14,363 |
|
|
$ |
308 |
|
|
2.1 |
|
% |
Restructuring expense |
|
|
59 |
|
|
|
114 |
|
|
|
(55 |
) |
|
|
|
|
Adjusted operating income (non-GAAP) |
|
$ |
14,730 |
|
|
$ |
14,477 |
|
|
$ |
253 |
|
|
1.7 |
|
% |
Operating margin (GAAP) |
|
|
16.7 |
|
% |
|
17.0 |
|
% |
|
|
|
|
|
||
Operating margin (non-GAAP) |
|
|
16.7 |
|
% |
|
17.1 |
|
% |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Home Office: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating loss (GAAP) |
|
$ |
(10,244 |
) |
|
$ |
(12,431 |
) |
|
$ |
2,187 |
|
|
17.6 |
|
% |
Restructuring expense |
|
|
177 |
|
|
|
562 |
|
|
|
(385 |
) |
|
|
|
|
Business integration expense |
|
|
— |
|
|
|
5,262 |
|
|
|
(5,262 |
) |
|
|
|
|
Debt modification costs |
|
|
712 |
|
|
|
— |
|
|
|
712 |
|
|
|
|
|
Adjusted operating loss (non-GAAP) |
|
$ |
(9,355 |
) |
|
$ |
(6,607 |
) |
|
$ |
(2,748 |
) |
|
(41.6 |
) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
70,238 |
|
|
$ |
28,194 |
|
|
$ |
42,044 |
|
|
149.1 |
|
% |
Restructuring expense |
|
|
2,094 |
|
|
|
676 |
|
|
|
1,418 |
|
|
|
|
|
Business integration expense |
|
|
— |
|
|
|
5,262 |
|
|
|
(5,262 |
) |
|
|
|
|
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
|
10,677 |
|
|
|
(7,872 |
) |
|
|
|
|
Litigation reserve |
|
|
— |
|
|
|
18,500 |
|
|
|
(18,500 |
) |
|
|
|
|
Debt modification costs |
|
|
712 |
|
|
|
— |
|
|
|
712 |
|
|
|
|
|
Adjusted operating income (non-GAAP) |
|
$ |
75,849 |
|
|
$ |
63,309 |
|
|
$ |
12,540 |
|
|
19.8 |
|
% |
Operating margin (GAAP) |
|
|
16.8 |
|
% |
|
7.6 |
|
% |
|
|
|
|
|
||
Operating margin (non-GAAP) |
|
|
18.2 |
|
% |
|
17.2 |
|
% |
|
|
|
|
|
Non-GAAP Adjusted EBITDA by Segment (unaudited) (in thousands) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
||||||||||||||
|
|
|
||||||||||||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
|||||||
|
|
2024 |
|
2023 |
|
$ |
|
% |
|
|||||||
Chamberlain: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
25,974 |
|
|
$ |
24,324 |
|
|
$ |
1,650 |
|
|
6.8 |
|
% |
Restructuring expense |
|
|
1,858 |
|
|
|
— |
|
|
|
1,858 |
|
|
|
|
|
Depreciation |
|
|
5,368 |
|
|
|
4,116 |
|
|
|
1,252 |
|
|
|
|
|
Amortization of cloud computing implementation assets |
|
|
652 |
|
|
|
200 |
|
|
|
452 |
|
|
|
|
|
Stock-based compensation |
|
|
3,119 |
|
|
|
2,907 |
|
|
|
212 |
|
|
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
36,971 |
|
|
$ |
31,547 |
|
|
$ |
5,424 |
|
|
17.2 |
|
% |
Adjusted EBITDA margin (non-GAAP) |
|
|
22.0 |
|
% |
|
22.1 |
|
% |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Walden: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
39,837 |
|
|
$ |
1,938 |
|
|
$ |
37,899 |
|
|
1,955.6 |
|
% |
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
|
10,677 |
|
|
|
(7,872 |
) |
|
|
|
|
Litigation reserve |
|
|
— |
|
|
|
18,500 |
|
|
|
(18,500 |
) |
|
|
|
|
Depreciation |
|
|
1,682 |
|
|
|
1,974 |
|
|
|
(292 |
) |
|
|
|
|
Amortization of cloud computing implementation assets |
|
|
701 |
|
|
|
188 |
|
|
|
513 |
|
|
|
|
|
Stock-based compensation |
|
|
2,740 |
|
|
|
1,864 |
|
|
|
876 |
|
|
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
47,765 |
|
|
$ |
35,141 |
|
|
$ |
12,624 |
|
|
35.9 |
|
% |
Adjusted EBITDA margin (non-GAAP) |
|
|
29.6 |
|
% |
|
24.8 |
|
% |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical and Veterinary: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating income (GAAP) |
|
$ |
14,671 |
|
|
$ |
14,363 |
|
|
$ |
308 |
|
|
2.1 |
|
% |
Restructuring expense |
|
|
59 |
|
|
|
114 |
|
|
|
(55 |
) |
|
|
|
|
Depreciation |
|
|
2,569 |
|
|
|
2,892 |
|
|
|
(323 |
) |
|
|
|
|
Amortization of cloud computing implementation assets |
|
|
283 |
|
|
|
52 |
|
|
|
231 |
|
|
|
|
|
Stock-based compensation |
|
|
1,607 |
|
|
|
1,640 |
|
|
|
(33 |
) |
|
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
19,189 |
|
|
$ |
19,061 |
|
|
$ |
128 |
|
|
0.7 |
|
% |
Adjusted EBITDA margin (non-GAAP) |
|
|
21.8 |
|
% |
|
22.5 |
|
% |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Home Office: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating loss (GAAP) |
|
$ |
(10,244 |
) |
|
$ |
(12,431 |
) |
|
$ |
2,187 |
|
|
17.6 |
|
% |
Restructuring expense |
|
|
177 |
|
|
|
562 |
|
|
|
(385 |
) |
|
|
|
|
Business integration expense |
|
|
— |
|
|
|
5,262 |
|
|
|
(5,262 |
) |
|
|
|
|
Debt modification costs |
|
|
712 |
|
|
|
— |
|
|
|
712 |
|
|
|
|
|
Depreciation |
|
|
184 |
|
|
|
356 |
|
|
|
(172 |
) |
|
|
|
|
Stock-based compensation |
|
|
1,985 |
|
|
|
1,044 |
|
|
|
941 |
|
|
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
(7,186 |
) |
|
$ |
(5,207 |
) |
|
$ |
(1,979 |
) |
|
(38.0 |
) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income (GAAP) |
|
$ |
46,165 |
|
|
$ |
10,646 |
|
|
$ |
35,519 |
|
|
333.6 |
|
% |
Loss from discontinued operations |
|
|
80 |
|
|
|
1,313 |
|
|
|
(1,233 |
) |
|
|
|
|
Interest expense |
|
|
14,482 |
|
|
|
15,657 |
|
|
|
(1,175 |
) |
|
|
|
|
Other income, net |
|
|
(2,646 |
) |
|
|
(2,214 |
) |
|
|
(432 |
) |
|
|
|
|
Provision for income taxes |
|
|
12,157 |
|
|
|
2,792 |
|
|
|
9,365 |
|
|
|
|
|
Operating income (GAAP) |
|
|
70,238 |
|
|
|
28,194 |
|
|
|
42,044 |
|
|
|
|
|
Depreciation and amortization |
|
|
14,244 |
|
|
|
20,455 |
|
|
|
(6,211 |
) |
|
|
|
|
Stock-based compensation |
|
|
9,451 |
|
|
|
7,455 |
|
|
|
1,996 |
|
|
|
|
|
Restructuring expense |
|
|
2,094 |
|
|
|
676 |
|
|
|
1,418 |
|
|
|
|
|
Business integration expense |
|
|
— |
|
|
|
5,262 |
|
|
|
(5,262 |
) |
|
|
|
|
Litigation reserve |
|
|
— |
|
|
|
18,500 |
|
|
|
(18,500 |
) |
|
|
|
|
Debt modification costs |
|
|
712 |
|
|
|
— |
|
|
|
712 |
|
|
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
96,739 |
|
|
$ |
80,542 |
|
|
$ |
16,197 |
|
|
20.1 |
|
% |
Adjusted EBITDA margin (non-GAAP) |
|
|
23.2 |
|
% |
|
21.8 |
|
% |
|
|
|
|
|
Non-GAAP Earnings Disclosure (unaudited) (in thousands, except per share data) |
||||||||
|
|
|
|
|
|
|
||
|
|
Three Months Ended |
||||||
|
|
|
||||||
|
|
2024 |
|
2023 |
||||
Net income (GAAP) |
|
$ |
46,165 |
|
|
$ |
10,646 |
|
Restructuring expense |
|
|
2,094 |
|
|
|
676 |
|
Business integration expense |
|
|
— |
|
|
|
5,262 |
|
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
|
10,677 |
|
Litigation reserve and debt modification costs |
|
|
712 |
|
|
|
18,500 |
|
Income tax impact on non-GAAP adjustments (1) |
|
|
(1,332 |
) |
|
|
(7,693 |
) |
Loss from discontinued operations |
|
|
80 |
|
|
|
1,313 |
|
Adjusted net income (non-GAAP) |
|
$ |
50,524 |
|
|
$ |
39,381 |
|
(1) |
Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. |
|
|
|
|
|
|
|
||
|
|
Three Months Ended |
||||||
|
|
|
||||||
|
|
2024 |
|
2023 |
||||
Diluted earnings per share (GAAP) |
|
$ |
1.18 |
|
|
$ |
0.25 |
|
Effect on diluted earnings per share: |
|
|
|
|
|
|
||
Restructuring expense |
|
|
0.05 |
|
|
|
0.02 |
|
Business integration expense |
|
|
- |
|
|
|
0.12 |
|
Amortization of acquired intangible assets |
|
|
0.07 |
|
|
|
0.25 |
|
Litigation reserve and debt modification costs |
|
|
0.02 |
|
|
|
0.44 |
|
Income tax impact on non-GAAP adjustments (1) |
|
|
(0.03 |
) |
|
|
(0.18 |
) |
Loss from discontinued operations |
|
|
0.00 |
|
|
|
0.03 |
|
Adjusted earnings per share (non-GAAP) |
|
$ |
1.29 |
|
|
$ |
0.93 |
|
Diluted shares used in non-GAAP EPS calculation |
|
|
39,109 |
|
|
|
42,184 |
|
Note: May not sum due to rounding. | ||
(1) |
Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. |
Non-GAAP Free Cash Flow Disclosure (unaudited) (in thousands) |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Three Months Ended |
|
Twelve Months Ended |
|
||||||||||||||||||||||||
|
FY24 |
|
FY25 |
|
FY24 |
|
FY24 |
|
FY24 |
|
FY24 |
|
FY25 |
|
||||||||||||||
|
Q1 |
|
Q1 |
|
Q1 |
|
Q2 |
|
Q3 |
|
Q4 |
|
Q1 |
|
||||||||||||||
Net cash provided by operating activities-continuing operations (GAAP) |
$ |
86,114 |
|
|
$ |
89,567 |
|
|
$ |
189,501 |
|
|
$ |
227,600 |
|
|
$ |
276,843 |
|
|
$ |
288,367 |
|
|
$ |
291,820 |
|
|
Capital expenditures |
|
(10,434 |
) |
|
|
(10,414 |
) |
|
|
(31,070 |
) |
|
|
(38,713 |
) |
|
|
(44,137 |
) |
|
|
(48,893 |
) |
|
|
(48,873 |
) |
|
Free cash flow (non-GAAP) |
$ |
75,680 |
|
|
$ |
79,153 |
|
|
$ |
158,431 |
|
|
$ |
188,887 |
|
|
$ |
232,706 |
|
|
$ |
239,474 |
|
|
$ |
242,947 |
|
|
|
|
|
Non-GAAP Net Leverage Disclosure (unaudited) (in thousands) |
||||
|
|
|
||
|
Twelve Months Ended |
|
||
|
|
|
||
|
|
|
||
Net income (GAAP) |
$ |
172,296 |
|
|
Income from discontinued operations |
|
(297 |
) |
|
Interest expense |
|
62,484 |
|
|
Other income, net |
|
(10,974 |
) |
|
Provision for income taxes |
|
35,589 |
|
|
Depreciation and amortization |
|
72,241 |
|
|
Stock-based compensation |
|
27,943 |
|
|
Restructuring expense |
|
3,288 |
|
|
Business integration expense |
|
28,953 |
|
|
Loss on assets held for sale |
|
647 |
|
|
Debt modification costs |
|
1,560 |
|
|
Adjusted EBITDA (non-GAAP) |
$ |
393,730 |
|
|
|
|
|
||
|
|
|
||
Long-term debt |
$ |
658,283 |
|
|
Less: Cash and cash equivalents |
|
(264,798 |
) |
|
Net debt (non-GAAP) |
$ |
393,485 |
|
|
|
|
|
||
Net leverage (non-GAAP) |
1.0 x |
|
||
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029106618/en/
Investor Contact
Investor.Relations@Adtalem.com
+1 312-906-6600
Media Contact
AdtalemMedia@Adtalem.com
+1 872-270-0301
Source: